ANI Pharmaceuticals receives ​​​​​​​FDA nod for generic Furadantin

ANI Pharmaceuticals has received the Food and Drug Administration’s green light for nitrofurantoin oral suspension, 25 mg/5 ml, which is the generic of Shionogi’s Furadantin.

The medication is an antibiotic used to treat or prevent certain bladder infections.

Nitrofurantoin oral suspension has a market value of approximately $55.5 million, according to IQVIA.

[Read more: ANI Pharmaceuticals launches 2 generics]

"New product approvals and launches remain our top priority as we continue to grow our generics business. The FDA approval and commercialization of nitrofurantoin oral suspension is another example of how we are continuing to bring limited-competition products to market, with the goal of serving the patient populations that can benefit,” said Nikhil Lalwani, president and CEO of ANI.